Clinical Trials Logo

C-met Overexpression clinical trials

View clinical trials related to C-met Overexpression.

Filter by:
  • None
  • Page 1

NCT ID: NCT01892527 Completed - Clinical trials for Colorectal Cancer Metastatic

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Start date: March 2013
Phase: Phase 2
Study type: Interventional

This is a single-arm, Simon 2-stage, phase 2 clinical study conducted in subjects with advanced or metastatic colorectal cancer who have previously received ≥ 1 prior line of systemic therapies and are resistant to EGFR inhibitor (cetuximab or panitumumab). This trial will be conducted to determine objective response rate (ORR), progression-free survival (PFS) and overall-survival (OS) of cetuximab plus tivantinib in patients with wild-type KRAS CRC that is resistant to anti-EGFR antibody treatment (cetuximab or panitumumab) and shows overexpression of cMET.